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OBJECTIVES: The composition of the small intestinal microbiota has not yet been characterized thoroughly using
culture-independent techniques.We compared small intestinalmicrobial communities in patientswith
and without small intestinal bacterial overgrowth (SIBO) using culture-dependent and culture-
independent bacterial identification approaches.
METHODS: Small bowel aspirate and mucosal samples were collected from patients with suspected SIBO. The
aspirates were cultured to diagnose SIBO, defined as ‡104 colony-forming units/mL coliform or ‡105
colony-forming units/mL upper aerodigestive tract bacteria. Bacteria in the aspirates andmucosa were
identified using 16S rRNA gene sequencing. We compared small intestinal microbiome composition
between groups with and without a culture-based SIBO diagnosis.
RESULTS: Analysis of the aspirate and mucosal microbial communities from 36 patients revealed decreased
a-diversity but no differences in b-diversity in patients with SIBO compared with those without SIBO.
There were no significant differences in the relative abundance of individual taxa from the aspirates or
mucosa after adjustment for false discovery rate between patients with and without SIBO. Subgroup
analysis revealed significant differences in mucosal b-diversity between the coliform and upper
aerodigestive tract subgroups. Relative abundances of a mucosal Clostridium spp. (P5 0.05) and an
aspirate Granulicatella spp. (P5 0.02) were higher in coliform SIBO vs non-SIBO subgroups. The
microbial composition and relative abundance ofmultiple taxa significantly differed in themucosal and
aspirate specimens.
DISCUSSION: Culture-based results of small bowel aspirates donot correspond to aspiratemicrobiota composition but
may be associated with species richness of the mucosal microbiota.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A89
Clinical and Translational Gastroenterology 2019;10:e00073. https://doi.org/10.14309/ctg.0000000000000073
INTRODUCTION
Small intestinal bacterial overgrowth (SIBO) has historically been
described in the context of maldigestion and malabsorption in
patients with anatomic abnormalities (e.g., fistulae, strictures,
bowel reconstruction, bowel obstruction), underlying dysmotility
secondary to diabetes or scleroderma, and hypochlorhydria
(1). This syndrome has also been implicated in the pathophysiol-
ogy of numerous gastrointestinal and hepatobiliary diseases in-
cluding common conditions such as irritable bowel syndrome
(IBS) (2) and functional dyspepsia (3). Typical SIBO-associated
symptoms include bloating, diarrhea, abdominal pain, and gas.
SIBO symptoms may overlap with those of functional gastroin-
testinal disorders. However, the role of SIBO in the pathogenesis of
functional gastrointestinal disorders remains controversial given
that its definition relies on tests, including breath test and culture of
small bowel aspirates, which have not been appropriately validated
(4). Indirect techniques such as breath testing have important
limitations related to heterogeneous testing methods and lack of
standardization in interpretation. To address these limitations,
guidelines for breath testing indications, performance, and
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interpretation were recently published in a North American con-
sensus document (5). Yet, there remain important knowledge gaps
in how these tests reflect the microbial landscape of the human
small intestine.
Small bowel aspirates and culture were previously considered
the gold standard for the diagnosis of SIBO. SIBO has tradi-
tionally been defined by abnormally high amounts of bacteria in
the small intestine and more precisely by .105 colony-forming
units (CFU)/mL of colonic-type bacteria from jejunal aspirates
(6). However, the validity of this approach has been questioned as
the proposed cutoff of 105 seemedmore predictive of postsurgical
patients in a previous systematic review (7). Others have sug-
gested that lower cutoff values of 103 CFU/mL be considered as
diagnostic of SIBO (5), especially if coliforms are present (8).
Standard culture-based techniques are limited in their ability to
characterize fully the complex diversity of the small intestinal
microbiome, particularly as a large proportion of bacterial species
remain uncultured (9). In light of increasing evidence supporting
the hypothesis that the intestinal microbiome serves a key role in
host physiology and gastrointestinal disease, better character-
ization of the small intestinal microbiome will be a critical step in
developing novel diagnostic and therapeutic strategies in a num-
ber of human diseases and disorders.
In the recent years, the introduction of culture-independent
techniques has dramatically expanded our ability to characterize
the complexity of the intestinalmicrobiota. It alsohas increasedour
knowledge of the culture conditions needed to detect and identify
previously difficult to culture organisms (10). Integration of rapid
molecular approaches (11) for the assessment of SIBO in con-
ditions such as IBS has yielded promising data including evidence
for decreased microbial diversity from duodenal aspirates in
patients with IBS compared with control subjects (12). However,
these findings are preliminary. Overall, there are limited data
reporting detailed characterizations of the human small intestinal
microbiome. It may be hypothesized that alterations in the small
intestinal microbiome are associated with culture-proven SIBO,
which in turn could suggest that although imperfect, culture-
proven SIBO is at least a useful surrogatemarker of small intestinal
dysbiosis. However, further investigation is needed to (i) explore
the role of microbial diversity in SIBO using culture-independent
approaches and (ii) describe the interactions between the host and
small intestinal microbiome in the context of gastrointestinal dis-
ease. This study characterizes small intestinal microbial composi-
tion of small bowel aspirates and mucosal specimens in patients
with and without a diagnosis of SIBO defined by qualitative and
quantitative culture of proximal small bowel aspirates.
METHODS
Study design and participants
We conducted a cross-sectional study comparing microbial
profiles of small bowel specimens in patients with and without
a culture-based diagnosis of SIBO presenting to the Motility and
Neurogastroenterology Clinic at Indiana University fromMarch
2013 to November 2015. The study protocol was approved by the
Indiana University School of Medicine Institutional Review
Board. Participants were prospectively enrolled after signing in-
formed consent at the time of small bowel enteroscopy. All
patients with suspected SIBO based on clinical symptoms and
undergoing small bowel enteroscopy for diagnostic evaluation
were eligible for inclusion regardless of clinical history. We ex-
cluded patients using antibiotics, probiotics, or colon cleansing
preparations in the last 30 days before enteroscopy and those who
were pregnant or could not provide informed consent.
Variables
Demographic data (age, gender, race/ethnicity) and anthropo-
metric assessments (body mass index [BMI], kg/m2) were col-
lected at the time of enrollment. Clinical history was reviewed to
assess for the presence of abdominal distension, diarrhea, and the
risk factors for SIBO including conditions (e.g., proton pump
inhibitor use) and surgeries associated with decreased acid pro-
duction (e.g., Billroth I or II, vagotomy, gastric bypass for obesity)
(13). Clinical symptoms were further assessed using the validated
Patient Assessment of Gastrointestinal Disorder-Symptoms Se-
verity Index questionnaire (14). All demographic and clinical
data were collected on enrollment and before the assessment of
SIBO status to minimize potential for information bias. Out-
comes of interest were (i) quantitative and qualitative cultures of
jejunal aspirates and (ii) microbial composition of jejunal aspi-
rates and mucosal biopsy specimens.
Study procedures
Study participants underwent upper enteroscopy using a pediatric
colonoscope (11.3 mm diameter) or a small caliber upper entero-
scope (9.2 mm diameter) for the collection of luminal aspirate and
mucosal biopsy specimens within the proximal jejunum using
a standardized protocol as previously detailed (13). Procedure
details are outlined in the supplementary material (see Table,
Supplemental Digital Content, http://links.lww.com/CTG/A89),
which outlines the procedures for enteroscopy. The enteroscope
was advanced past the ligament of Treitz to themaximum extent of
reach into the jejunum, and an aspiration catheter was introduced
through theworking channel to collect at least 2mLof luminalfluid.
After the collection of luminal aspirates, 2 mucosal biopsies were
obtained from the proximal jejunum on withdrawal of the endo-
scope. Mucosal biopsy samples were stored at 280 °C for sub-
sequent 16S rRNAanalysis. Jejunal aspirate sampleswere split at the
time of collection to be sent for quantitative and qualitative bacterial
cultures and to be stored at 280 °C for subsequent polymerase
chain reaction analysis.
Quantitative culture of jejunal aspirates
Small bowel aspirates were cultured for both aerobic and anaer-
obic bacteria using standard techniques. Aspirate specimens were
plated on blood agar, MacConkey agar, chocolate agar, and co-
listin and nalidixic acid agar plates, and incubated for aminimum
of 48 hours. Bacterial isolates were identified by species and
quantified as CFU/mL. Given the lack of a universally accepted
cutoff for defining SIBO at the time this study was conducted, we
used the following thresholds to define coliform and upper aer-
odigestive tract (UAT) SIBO, respectively: (i) presence of $104
CFU/mL Gram-negative aerobic and anaerobic colonic-type
bacteria (e.g., Escherichia coli spp, Klebsiella spp, Proteus mir-
abilis, Acinetobacter spp, Enterobacter spp, Citrobacter spp,
Bacteroides spp, or Clostridium spp) and (ii) presence of $105
CFU/mLGram-positive aerobes or facultative anaerobes or other
bacteria characteristic of the proximal gut and oropharynx (e.g.,
Streptococcus spp, Staphylococcus spp, Enterococcus spp, Lacto-
bacillus spp, Fusobacterium spp, or Peptostreptococcus spp)
(4,15,16). Participants were classified as having SIBO if the cul-
ture results revealed evidence of either UAT or coliform SIBO.
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Molecular analysis of jejunal aspirates and mucosal
biopsy specimens
Luminal aspirate samples and mucosal biopsy samples were
thawed on ice. Total nucleic acids were extracted using the
DNeasy tissue kit (Qiagen, Venlo, The Netherlands), and the
eluted DNA was stored at 220 °C. Gel electrophoresis and
fluorescent assay (Qubit assay kit; Life Technologies, Carlsbad,
CA) were used to determine the quality and quantity of isolated
genomic DNA (gDNA). gDNA specimens were stored at 4 °C for
immediate use in 16S rRNA sequencing. Polymerase chain re-
action amplification of V1–V3 regions of 16S rRNA alleles was
performed using degenerate 16S rRNA primers with a barcoding
strategy previously validated by our laboratory. Reagent controls
were processed in parallel to monitor for contamination. Nor-
malized amplicon libraries were pooled and sequenced using the
IlluminaMiSeq sequencer (Illumina, SanDiego, CA)using paired
300 bp reads to generate 4,765,249 total reads. 16S sequences were
processed and fed into the Mothur package (v1.37.4) to generate
lists of microbial taxa and relative loads. Subsampling at a depth
of 1,563 total reads was performed for each sample to correct for
biases caused by differential sequencing depth. Consensus
sequences or contigs were identified by overlapping paired end
reads. The standard operating procedure of Mothur for MiSeq
data processing was used to trim primers and barcodes from each
read and to remove chimeric and low-quality sequences. Oper-
ational taxonomic units (OTUs) were identified with a sequence
similarity cutoff at 0.97, and the representative OTUs were
taxonomy classified using the RDP classifier (v2.11) (17) at the
genus level and Bayesian Lowest CommonAncestor method (18)
at the species level. The R software environment (https://www.r-
project.org/) was used to calculate standard ecologicala-diversity
(Observed taxa, Chao1 metrics; S. ACE; Shannon; Simpson;
Pielou evenness) with vegan package. Principal coordinate
analysis (ape package in R) (19) and nonmetric dimensional
scaling method were applied to cluster samples based on Bray-
Curtis dissimilarities (ecodist package inR) (20) in anticipation of
comparative analyses of b-diversity.
Study endpoints
The primary study endpoint was overall microbial diversity.
Secondary endpoints were relative abundance and prevalence of
specific bacterial taxa.
Study size
Sample size was determined by the number of available cases
during the study period. No formal a priori calculation for sample
size was performed for this pilot investigation.
Statistical analysis
Pairwise comparisons of a-diversity indexes between cohorts were
performed using theWilcoxon rank sum test. Principal coordinate
analysis and nonmetric dimensional scaling were used to visualize
and compare Bray-Curtis dissimilarity, and comparisons between
groupswere performed using the PERMANOVAapproach adjusting
Figure 1. Results of quantitative bacterial cultures from jejunal aspirates from individual participants. Quantitative bacterial cultures are shown in units of
1–5 (15 present, 25,10,000 CFU/mL, 35 10,000–49,999 CFU/mL, 45 50,000–99,999 CFU/mL, 55$100,000 CFU/mL). Participants along the
X‐axis are labeled by final SIBO diagnosis as defined by culture results (05 no SIBO, 15UAT SIBO, 25 coliform SIBO). CFU, colony-forming unit; SIBO,
small intestinal bacterial overgrowth; UAT, upper aerodigestive tract.
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for BMI.We also uncovered associations between clinical cohorts and
specific bacterial taxa by comparing relative taxa abundance between
groups using a linear model adjusting for BMI. A negative binomial
regression with mixed model for repeat measurements was applied
to analyze the differences in relative abundance of specific bacterial
taxa between the groups. Differences in community composition
across sampling sites (aspirate vs mucosa) were examined by Bray-
Curtis dissimilarities using thePERMANOVAapproach.To explore
potential heterogeneity related to cultured bacterial types, we also
conducted predefined subgroup analyses comparing patients with
a diagnosis of coliform SIBO, UAT SIBO, and no SIBO.
Participants with missing data were excluded from the
analyses; all statistical tests were performed using the R soft-
ware environment (http://www.r-project.org). Analyses were
confined to taxa with relative abundance of .0.1% in any one
of the cohort groups. Two-sided P-values, 0.05 were regarded
as significant. Reported P values were corrected for multiple
testing using the Benjamini-Hochberg procedure. All sequen-
ces and associated metadata were deposited to the NCBI Se-
quence Read Archive under the BioProject ID PRJNA472002.
RESULTS
Patient characteristics
Among the 86 patients who signed informed consent, 76
completed upper enteroscopy with luminal aspiration. 16S
sequencing data from either luminal aspirates or biopsy
specimens were available in 36 of the 76 patients, of whom 15
had a diagnosis of SIBO based on the culture of jejunal aspi-
rates. 16S sequencing data were not available in 40 patients due
to factors related to specimen processing and storage and lab-
oratory handling. Bacterial species cultured from jejunal aspi-
rates of all participants are shown in Figure 1. For the overall
cohort, mean BMI (kg/m2)6 SD was 26.56 7.1 and mean age
(years) 6 SD was 50.1 6 12.7. There were 33 female patients,
and 91.7% were white (Table 1). There were no significant
differences in age, race, gender, or BMI in between patients with
and without SIBO. Although conditions (e.g., proton pump
inhibitor use) and surgeries associated with decreased gastric
acid productionweremore common in patients with SIBO than
in patients without SIBO, these differences were not statistically
significant. No patients had evidence of mucosal atrophy based
on routine histologic evaluation. Comparison of clinical
symptoms between patients with and without SIBO showed no
significant differences in the proportion of patients reporting
diarrhea or daily abdominal distention (Table 1) or in Patient
Assessment of Gastrointestinal Disorder-Symptoms Severity
Index scores (14). Aspirate and biopsy specimens for 16S se-
quencing were obtained in 32 and 34 patients, respectively. In
some cases, sequencing data were available from only the as-
pirate or the biopsy specimen but not both. We were unable to
amplify bacterial 16S sequences from 2 of the 32 aspirate
specimens and 1 of the 34 biopsy specimens.
Table 1. Demographics and baseline characteristics among patients with and without SIBO by the culture of jejunal aspirates
Factor SIBO (n 5 15) No SIBO (n5 21) P value
Age (yr) 53.006 13.58 48.05 6 12.00 0.27
Female patients, n (%) 13 (86.7) 20 (95.2) 0.56
Race (% white) 13 (86.7) 20 (95.2) 0.56
Body mass index (kg/m2) 28.42 6 6.96 25.16 6 7.05 0.18
Condition associated with decreased gastric
acid production (e.g., PPI use), n (%)
10 (66.7) 8 (38.1) 0.18
Surgery associated with decreased gastric
acid, n (%)
4 (26.7) 1 (4.8) 0.14
Small bowel motility failure (e.g., chronic
intestinal pseudo-obstruction, radiation
enteropathy, visceral neuropathy, or
myopathy), n (%)
3 (20) 2 (9.5) 0.63
Diarrhea, n (%) 6 (40) 7 (33.3) 0.74
Daily abdominal distention, n (%) 8 (53.3) 12 (57.1) 0.35
PAGI-SYM total score 2.81 6 0.94 3.09 6 0.87 0.39
PAGI-SYM subscale scores
Heartburn/regurgitation 2.04 6 1.43 2.13 6 1.35 0.85
Nausea and vomiting 2.45 6 1.34 3.03 6 1.30 0.22
Postprandial fullness/early satiety 3.07 6 1.09 3.47 6 1.10 0.31
Bloating 3.64 6 1.51 3.55 6 1.53 0.86
Upper abdominal pain 2.92 6 1.43 3.57 6 1.00 0.17
Lower abdominal pain 2.36 6 1.47 2.83 6 1.12 0.32
Data show mean 6 SD values unless otherwise stated. Comparisons carried out using t test for continuous variables and Fisher exact test for categorical variables.
PAGI-SYM, patient assessment of upper gastrointestinal symptom severity index; PPI, proton pump inhibitor; SIBO, small intestinal bacterial overgrowth.
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Associations between overall microbial composition and SIBO
status by culture
Analysis of small intestinal microbial diversity revealed significantly
lowermucosala-diversity (Chao1,ACE) at the genus level (Figure 2)
in patients with SIBO compared with patients without SIBO. There
was no significant difference in luminal aspiratea-diversity (Chao1,
ACE, Shannon, Simpson, Pielou) between patientswith andwithout
SIBO. After adjusting for BMI, no significant differences were ob-
served in the aspirate or mucosal microbiota b-diversity (Bray-
Curtis dissimilarity) between patients with and without SIBO.
Single taxon-based analyses
Relative abundance ofmultiple individual taxa (Table 2) from the
aspirates and mucosa was significantly associated with SIBO di-
agnosis before but not after adjustment for false discovery rate
(FDR). Prevalence of individual bacterial taxa in the aspirates and
mucosa was not significantly associated with SIBO diagnosis.
However, there was a trend toward an increased prevalence of an
unassigned OTU (OTU 065) in those with SIBO compared with
those without SIBO (P 5 0.047).
Comparison of community composition across sampling sites
Significant differences in b-diversity (Bray-Curtis dissimilarity)
were observed between the aspirate and mucosal microbiota
(P 5 0.001) at the genus level. These differences remained sig-
nificant after including subject and BMI as confounding factors.
Significant differences were also observed in the relative abun-
dance of multiple individual taxa (Table 3) between the aspirates
and mucosa at both genus and OTU levels.
Subgroup analysis of SIBO cohorts by culture type
Significant differences in mucosal microbiota b-diversity were
observed between patients with coliform and UAT SIBO
(Figure 3). There were no differences in mucosal microbiota
a-diversity among subgroups (no SIBO,UATSIBO, and coliform
SIBO). Comparisons of taxonomic-level datasets (Table 4)
showed an increase in the relative abundance of a Clostridium
spp. in mucosal specimens of patients with coliform SIBO vs
patients without SIBO (P 5 0.05) after correcting for FDR.
Granulicatella spp. was also enriched in the aspirates of patients
with coliform SIBO vs patients without SIBO (P 5 0.02) after
adjusting for BMI and correcting for FDR. OTU level analyses
showed a higher abundance of aClostridium perfringens-assigned
OTU in the mucosa of patients with coliform SIBO compared
with patients without SIBO before (P5 0.001) and after (P5 0.035)
adjusting forBMIandcorrecting for FDR.AGranulicatella-assigned
OTUwas enriched in the aspirates of patients with coliform SIBO vs
patients without SIBO after adjusting for BMI and correcting for
FDR (P 5 0.01). Prevalence of individual bacterial taxa from the
mucosal specimens was not significantly associated with culture
diagnosis. Prevalence of Clostridium sensu stricto in the luminal
aspirates of patientswith coliformSIBO (24%)was higher (P50.04)
than in patients without SIBO (0.01%) or UAT SIBO (0%). There
were no significant differences in the relative abundance of in-
dividual taxa in the aspirates or mucosa between patients with UAT
SIBO and those with coliform SIBOnor between patients withUAT
SIBO and patients without SIBO at either taxonomic level. Relative
abundances of individual bacterial taxa in the aspirates and mucosa
from each individual are shown in Figure 4.
DISCUSSION
In this pilot investigation, we compared luminal aspirate and
mucosal microbial communities from patients with and without
a culture-based diagnosis of SIBOof the proximal gastrointestinal
tract. To date, there are only a handful of studies that have ex-
amined the small intestinal microbiome. Relatively little is known
regarding its role in symptom generation, although recent data
have suggested that the small intestinalmicrobiome, but not SIBO
based on quantitative culture of small bowel aspirates, is associ-
ated with gastrointestinal symptoms (21). In our study, we made
several interesting observations. First, comparison of microbial
communities revealed lower a-diversity (Chao1, ACE index) at
the genus level in the mucosal microbiome of patients with SIBO
compared with patients without SIBO, but no significant differ-
ences in aspirate microbiota a- or b-diversity or in the mucosal
microbiota b-diversity were noticed. Findings suggest that
whereas mucosal microbial richness (i.e., a-diversity) is de-
creased in culture-diagnosed SIBO, there are no clear differences
at the community level (i.e.,b-diversity) or in the luminal aspirate
microbiota composition. Our findings are consistent with a re-
cently published report that found a lack of correlation between
aspirate microbial composition and duodenal aspirate cultures in
SIBO (21). These findings may imply that although small bowel
cultures may not reflect luminal aspirate microbial composition,
the overgrowth of luminal microbes may be associated with
changes in the mucosal microbiota.
Figure 2. Small intestinal mucosal microbiota demonstrates lower
a-diversity in patients with SIBO vs patients without SIBO. SIBO, small
intestinal bacterial overgrowth. Alpha diversity determined using Obs (a),
Chao1 (b), ACE (c), Shannon (d), Simpson (e), and Pielou (f) indices.
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Second, analysis by subgroup went on to reveal significant
differences in mucosal microbiota b-diversity between patients
with coliform SIBO and those with UAT SIBO, suggesting that
there may be differences in the community composition of the
mucosal microbiota between these 2 SIBO subgroups. These
observations may further suggest that the overall SIBO cohort
encompasses 2 heterogeneous groups (coliform and UAT SIBO).
By combining these groups using broad culture-based cutoffs, we
may be diluting our ability to appreciate important differences in
the community composition of the luminal and mucosal micro-
biota between patients with and without bacterial overgrowth.
Single taxon-based testing suggested that the relative abun-
dance of multiple taxa in the aspirate andmucosa of patients with
SIBO differed from those of patients without SIBO before but not
after adjustment for FDR. Overall results support the long-
standing concern that cultivating bacteria in the laboratory does
not clearly represent pathologic shifts in the members of the
microbial community and is largely insufficient for characterizing
the complex microbial composition of the gut.
Subgroup analyses further demonstrated enrichment of
Clostridium spp. and a C. perfringens-assigned OTU in the mu-
cosa of patients with coliform SIBO compared with those without
SIBO as well as enrichment of Granulicatella spp. and a Gran-
ulicatella-assigned OTU in the luminal aspirates of patients with
coliform SIBO compared with those without SIBO. Enter-
otoxinogenic C. perfringens is an important cause of food-borne
illnesses and other gastrointestinal diseases such as antibiotic-
associated diarrhea (22,23). Higher levels of fecal C. perfringens
have been described in elderly individuals residing in long-term
care. The presence of C. perfringens in these individuals was as-
sociated with significant changes in microbiota composition
including decreased levels of Bifidobacterium spp., suggesting
that C. perfringens recovery in the stool may reflect a less healthy
microbiota (24).Granulicatella spp. areGram-positive facultative
anaerobes that are considered a normal part of the oral bacter-
iome but have been shown to be increased in patients with cir-
rhosis with hepatic encephalopathy (25) compared with patients
with cirrhosis without encephalopathy. Granulicatella spp. have
also been shown to coaggregate with other bacterial species im-
plicated in dental plaque biofilm formations, such as Aggregati-
bacter actinomycetemcomitans and Fusobacterium nucleatum
(26). Although preliminary, our findings may suggest increased
relative abundance of mucosal Clostridium spp. and/or luminal
Granulicatella spp. may serve as a microbial marker for dis-
turbances in the small intestinal microbiota in patients with co-
liform SIBO. Findings could also indicate that patients with
coliform SIBO may have increased susceptibility to infection by
pathogenic microorganisms or abnormal commensal expansion.
Lack of significant differences with single-taxon analyses between
patients with UAT and coliform SIBO or between patients with
UAT and no SIBO may suggest considerable overlap between
these particular culture-based diagnostic subgroups.
Last, comparison of small intestinal microbiota composition
from the luminal aspirates and mucosal biopsies showed signif-
icant differences in b-diversity (Bray-Curtis dissimilarity) and
relative abundance of multiple bacterial taxa. Higher abundances
of members belonging to Prevotella and Fusobacterium were
observed in the mucosal microbiota compared with the luminal
microbiota, whereas higher abundances of the genera Strepto-
coccus and Actinomyces and the Lactobacillus gasseri-assigned
OTU were observed in the luminal aspirate microbiota. These
differences emphasize the distinct stratification of microbial
Table 2. Mean relative abundance of individual bacterial taxa
Factor SIBO No SIBO P value FDR-adjusted P value
Luminal aspirate microbiota
Genus
Granulicatella 4.11 6 4.79 1.26 2.80 0.0045 0.086
Rhodanobacter 0.20 6 0.28 1.15 6 2.46 0.017 0.121
Neisseria 4.96 6 18.68 0.05 6 0.06 0.025 0.121
Fusobacterium 1.24 6 1.99 0.49 6 0.80 0.025 0.121
OTU index
006 (Granulicatella adiacens) 4.25 6 5.02 2.24 6 2.94 0.0063 0.082
020 (Rhodanobacter spathiphylli) 0.23 6 0.28 1.05 6 2.33 0.051 0.223
011 (Fusobacterium nucleatum) 1.20 6 1.88 0.51 6 0.80 0.0458 0.223
Mucosal microbiota
Genus
Neisseria 4.02 6 14.91 0.70 6 1.91 0.005 0.136
Fusobacterium 1.20 6 1.02 3.04 6 5.70 0.04 0.548
OTU index
011 (F. nucleatum) 1.45 6 1.12 3.32 6 5.99 0.056 0.677
Comparisons carried out using negative binomial regression with mixed model for repeat measures. Correction for multiple testing applied using Benjamini-Hochberg
Procedure.OTUannotationperformedbyBayesian Lowest CommonAncestor software. Data representmean relative abundance (%)6SD.Data shown for taxawithmean
relative abundance 6 1%.
FDR, false discovery rate; OTU, operational taxonomic unit; SIBO, small intestinal bacterial overgrowth.
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communitieswithin the lumen andmucosa, which have previously
been described by others (27,28). It should be noted that there
remains a paucity of data describing the changes in microbial
composition from the lumen to the mucosa within the human
small intestine, which may be directly influenced by aspects of
perfusion and oxygen diffusion that are unique to this site (29).
The relative importance of the luminal microbiota compared with
the mucosa-associated microbiota in disease pathogenesis and the
interactionbetween these 2 communitieswill require further study.
This study has several strengths including prospective enroll-
ment of study participants with careful assessment of several fac-
tors associated with the gut microbiota (age, gender, BMI), use of
a standardized technique for the collection of study specimens by 2
experienced endoscopists, and concomitant application of both
traditional culture-based methods and culture-independent mo-
lecular approaches for the characterization of the small intestinal
bacteria. The proportion of patients meeting diagnostic criteria for
SIBO in this study was high, which was not unexpected given that
our site serves as a tertiary referral center and participants were
recruited from among those in whom a diagnosis of SIBO was
suspected based on the clinical history and symptoms. Study lim-
itations include the lack of nonmicrobial-defined patient groups
and the inability to study SIBO of the mid- and distal gastroin-
testinal tract. It is also possible that culture techniques were limited
in their ability to facilitate the growthof anaerobicorganismsdue to
potential exposure of specimens to air andmay, in some cases, have
been inadequate for the assessment of SIBO. Because the partic-
ipants were recruited among patients receiving clinical care at the
gastrointestinal motility clinic, study physicians could not be
blinded to the clinical history or results of previous testing, as this
informationwas pertinent to patient care.However, patient groups
were defined based on objective laboratory testing rather than
a clinical diagnosis, and investigators sought to enroll patients both
with and without a culture-based diagnosis of SIBO. Furthermore,
outcome assessments (i.e., laboratory-based culture results and
small intestinal microbiota based on culture-independent techni-
ques) were performed by study teammembers and bymembers of
Table 3. Significant differences observed in relative abundance of specific bacterial taxa in the aspirate and mucosal specimens in the
overall cohort
Factor Aspirate specimens Mucosal specimens P value FDR-adjusted P value
Genus
Prevotella 1.07 6 3.87 9.14 6 10.16 ,0.0001 ,0.0001
Streptococcus 58.85 6 24.67 31.60 6 21.47 ,0.0001 0.0008
Fusobacterium 0.81 6 1.45 2.24 6 4.39 0.0007 0.0043
Actinomyces 6.41 6 8.99 2.91 6 2.87 0.0096 0.0353
Lactobacillus 2.71 6 7.22 0.69 6 2.16 0.018 0.0619
Neisseria 2.10 6 12.06 2.14 6 9.92 0.032 0.0942
OTU index
003 (Prevotella melaninogenica) 1.04 6 3.74 10.16 6 11.36 ,0.0001 ,0.0001
011 (Fusobacterium nucleatum) 0.80 6 1.38 2.51 6 4.61 ,0.0001 ,0.0001
001 (Streptococcus mitis) 61.13 6 22.60 31.73 6 21.89 ,0.0001 0.0001
021 (Porphyromonas pasteri) 0.10 6 0.38 1.00 6 1.89 0.00017 0.0007
015 (Lactobacillus gasseri) 2.15 6 6.50 0.25 6 0.64 0.001 0.0039
004 (Actinomyces odontolyticus) 6.48 6 8.87 3.27 6 2.92 0.0094 0.0291
013 (Lachnoanaerobaculum orale) 1.72 6 2.20 0.99 6 1.06 0.012 0.0334
006 (Neisseria perflava) 2.22 6 12.82 2.18 6 9.80 0.019 0.0474
Comparisons carried out using negative binomial regression with mixed model for repeat measures. Correction for multiple testing applied using Benjamini-Hochberg
Procedure. OTU annotation performed by Bayesian Lowest Common Ancestor software. Data represent mean relative abundance (%) 6 SD.
FDR, false discovery rate; OTU, operational taxonomic unit.
Figure 3. Significant differences in mucosal microbiota b-diversity between
patients with coliform SIBO (black circles) and those with UAT SIBO (white
circles) at both (a) genus level and (b) OTU levels. SIBO, small intestinal
bacterial overgrowth; UAT, upper aerodigestive tract.
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the microbiology laboratory who were not directly involved with
patient care. Therefore, the impact of a potential selection bias on
study recruitment and outcomes due to lack of blinding is overall felt
to be minimal. Interpretation of findings are also limited by small
sample size and limited generalizability given that our institution
serves a tertiary referral center. We did not assess for methanogenic
archaea, which may be pathogenic contributors to SIBO (30).
However,posthoc analysisdidnot reveal any significantdifferences in
the relative abundance of methanogenic organisms such as Meth-
anobrevibacter spp. between thosewith andwithout SIBO.This is not
unexpected as comparison groups were defined based on standard
culture results and not on the results of breath testing for methane.
In conclusion, our study suggests that in patients with evi-
dence of proximal SIBObased on culture of small bowel aspirates,
luminal overgrowth is not correlated with luminal microbiota
composition. Instead, patients with a culture-based diagnosis of
proximal SIBO exhibit decreased mucosal microbial richness
(e.g., a-diversity). Additionally, mucosal community diversity
(e.g., b-diversity) differs between patients with coliform SIBO vs
those with UAT SIBO by culture, suggesting that they are distinct
microbiologic groups that should be examined separately to
better define the clinical utility of culture-based testing. Further
prospective investigations that examine the correlation between
symptom profiles and the small intestinal aspirate and mucosal
microbiota, incorporate deep sequencing techniques, and con-
sider functional and metabolomics profiling will be required to
better characterize the relevant microbial communities of the
small intestine and to identify future microbial targets for im-
proved diagnosis and management of SIBO.
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Study Highlights
WHAT IS KNOWN
3 SIBO remains a poorly defined clinical syndrome, and the
validity of currently available techniques to evaluate for
abnormal bacterial expansion in the small intestine has been
questioned.
3 The complexity and composition of the small intestinal
microbiome are incompletely understood.
WHAT IS NEW HERE
3 Patients with a culture-based diagnosis of SIBO show no
differences in aspirate microbiota composition but exhibit
decreased mucosal alpha-diversity, suggesting that
decreased mucosal microbial richness is associated with
luminal bacterial overgrowth.
3 Comparisons of patients with a culture-based diagnosis of
coliform SIBO and UAT SIBO suggest that the types of
bacterial species cultured are associated with distinct
changes in the community composition of the mucosal
microbiome.
3 Differences in the relative abundance of individual taxa
between patients with coliform and those with UAT SIBO
suggest that there may be abnormal expansion of specific
bacteria SIBO which are not directly identified by culture-
based testing.
TRANSLATIONAL IMPACT
3 Small intestinal mucosal microbiota and aspirate microbiota
are distinct in both community profile and relative abundance
of individual taxa, and studying the role of both will be
important in understanding the relative contribution of these 2
communities to clinical symptoms.
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